Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
for Locally Advanced Adrenal Cortical Carcinoma
Drug: Cabozantinib
Sites in Dallas, San Antonio +75 more locations
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 12+
Code: NCT06900595·Phase 2·Recruiting·Listed Mar 2025